Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

lipomed gmbh - thalidomid - multippelt myelom - immunsuppressive - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.

Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

krka, d.d., novo mesto  - telmisartan - hypertensjon - angiotensin ii antagonister, vanlig - hypertensiontreatment av essensiell hypertensjon hos voksne. kretsløpssystem preventionreduction av hjerte-sykdom hos pasienter med manifest atherothrombotic hjerte-og karsykdommer (history of coronary heart sykdom eller perifer arteriell sykdom) eller type 2 diabetes mellitus med dokumentert målorgan skade.

Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemi, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

biocryst ireland limited - berotralstat dihydrochloride - angioødemer, arvelig - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

dynavax gmbh - hepatitt b overflate antigen - hepatitt b - vaksiner - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - immune sera og immunglobuliner, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. se avsnitt 4. 4 og 5.

Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - pneumococcal polysaccharide conjugate vaccine (adsorbed) - pneumokokkerinfeksjoner - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. se avsnitt 4. 4 og 5. 1 for informasjon om beskyttelse mot spesifikke pneumokokserotyper. the use of vaxneuvance should be in accordance with official recommendations.

Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - immune sera og immunglobuliner, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

zoetis belgium - inaktivert bluetongue-virus, serotype 8, stamme btv-8 / bel2006 / 02 - immunologicals - kveg - active immunisation of cattle from three months of age for the prevention of viraemia caused by bluetongue virus, serotype 8.

Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertapenemnatrium - community-acquired infections; streptococcal infections; staphylococcal infections; gram-negative bacterial infections; surgical wound infection; pneumonia, bacterial - antibakterielle midler for systemisk bruk, - treatmenttreatment av følgende infeksjoner når forårsaket av bakterier som er kjent eller svært sannsynlig å bli utsatt for ertapenem og når parenteral behandling er nødvendig:intra-abdominal infeksjoner;samfunnet-ervervet lungebetennelse;akutt gynekologisk infeksjoner;diabetiker foten infeksjoner i hud og bløtvev. preventioninvanz er angitt i voksne for profylakse av kirurgiske området infeksjon etter elektiv kolorektal kirurgi. det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler.